source
- PepGen's Phase 2 DM1 Data Show 46% Average Splicing Correction, Shares Jump 163%PepGen reported results from the 10 mg/kg multiple‑ascending‑dose cohort of its ongoing Phase 2 Freedom2‑DM1 trial, testing PGN‑EDODM1, an oligonucleotide designed to correct the molecular defect i…
- Deerfield Management teams with AWS to boost AI-driven life-science venturesDeerfield Management announced a collaboration with Amazon Web Services aimed at accelerating AI-native healthcare and life-science companies in its portfolio. The agreement links AWS's generative…